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Abstract 
The definition of the standard chemotherapy regimen for advanced gastric cancer is still a matter of debate. Aim of 
our analysis was to retrospectively assess whether an intensive, three-drugs, front line approach could be comparable 
to a sequential (two-drugs front line then second line) in terms of RR (response rate), PFS (progression free survival) 
and OS (overall survival) in advanced gastric cancer patients in the clinical practice. Patients with metastatic gastric 
cancer who have received a first-line combination chemotherapy with a two or three-drugs regimen were included 
in our analysis. We divided our patients into two groups, A and B, based on the first line chemotherapy administered 
(group A = three drugs; group B = two drugs). A total of 425 patients were eligible for our analysis. 216 patients 
(50.8 %) received three chemotherapeutic agents (group A) and 209 patients (49.2 %) received a two drugs regimen 
as first-line combination chemotherapy (group B). RR for group A and B was 44 and 29.6 %, respectively (p = 0.0005), 
median PFS was 7.3 months in group A and 4.5 months in group B (p = 0.0007). No significant difference was found 
in terms of OS. The addition of a third drug to a doublet chemotherapy regimen appeared more active in terms of 
response rate and PFS. However median OS resulted comparable. On this basis, the use of a sequential approach 
may represent a reasonable strategy for patients unwilling or unable to undergo a more intensive treatment without 
compromising OS.
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Background
Gastric cancers remains one of the leading causes of 
cancer mortality worldwide even thought its incidence 
has been decreasing in recent years. Radical surgical 
resection still represents the only potentially curative 
treatment. Unfortunately, more than half of gastric 
carcinomas are diagnosed in an advanced stage, when 
resection is no longer possible. In this setting chemo-
therapy is still the main treatment option for patients 
with advanced disease. Median overall survival (OS) of 
8–12 months has been reported in patients undergoing 
chemotherapy compared with 3–5  months for those 
treated with best supportive care alone (Glimelius 
et al. 1997). Several drugs such as fluorouracil (5-FU), 
capecitabine, cisplatin, oxaliplatin docetaxel, epiru-
bicin, paclitaxel and irinotecan are major components 
of conventional regimens. S-1 and mytomicin C are 
also being used for the treatment of gastric cancer. 
Combination chemotherapy has been shown to be 
associated with a statistically significant (p  =  0.001) 
survival benefit compared to monotherapy in a meta-
analysis of several clinical trials (Wagner et  al. 2006). 
This corresponded to a small but clinically relevant 
1-month mean average survival benefit. This meta-
analysis also showed that including anthracyclines 
in a 5-FU-cisplatin combination had a modest sur-
vival advantage over cisplatin-5-FU alone (HR 0.77). 
Finally, the meta-analysis also showed that three-drug 
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combinations had a significant survival benefit com-
pared to two-drug combinations. Several clinical trials 
(Van Cutsem et  al. 2006; Ajani et  al. 2007a, b; Cun-
ningham et  al. 2008) investigating first-line therapy in 
advanced gastric cancer suggested that a triplet chem-
otherapy regimen might have a survival benefit over 
doublets but the evidence is not fully convincing since 
these results are mostly dependent on older studies. 
Adding more chemotherapeutic agents seems to confer 
more benefit but at the same time inevitably adds toxic-
ity, thus to date, a triplet chemotherapy combinations 
is not an established global standard as yet. Besides, in 
the daily clinical practice, administering a three-drugs 
treatment may prove difficult in advanced gastric can-
cer patients, who often present with multiple co-mor-
bidities and poor performance status. Consequently 
in this scenario a doublet with a fluoropyrimidine and 
platinum is still an acceptable alternative and remains 
the cornerstone of gastric cancer treatment. On this 
basis, the definition of the standard chemotherapy 
regimen for advanced gastric cancer remains a matter 
debate.
Aim of our analysis was to retrospectively assess 
whether an intensive, three-drugs, front line approach 
could be comparable to a sequential (two-drugs front 
line then second line) in terms of RR (response rate), PFS 
(progression free survival) and OS (overall survival) in 
advanced gastric cancer patients.
Patients and methods
Patients selection
The study population was selected from a central data-
base including patients with gastric cancer treated and 
followed at our institution. Patients with histologically 
confirmed, recurrent or metastatic gastric or gastroe-
sophageal junction adenocarcinoma who have received 
a first-line combination chemotherapy with a two or 
three-drugs chemotherapy regimen were included in our 
analysis. Patients were eligible if they had measurable or 
evaluable metastatic disease; Eastern Cooperative Oncol-
ogy Group performance status 0–2; age ≥18; no central 
nervous system metastasis. Patients treated with trastu-
zumab or were excluded from our analysis.
We divided patients into two groups, A and B, based 
on the characteristics of the first line chemotherapy 
combination used (group A  =  three drugs; group 
B  =  two drugs). The chemotherapy regimen adminis-
tered to each patient was chosen by the treating physi-
cian, mainly according to patient’s characterstics, such 
as age, performance status, comorbidities and organ 
function.
This analysis was approved by Ethical committee AOU 
Ospedali Riuniti, Umberto I of our institution.
Response to treatment
Physical examination, complete blood counts and bio-
chemical tests were carried out before each cycle of 
therapy. A chest and abdomen CT scan was performed 
every four cycles and when disease progression was clini-
cally suspected to document the extent of disease and 
to evaluate the response to treatment. The response was 
assessed using the Response Evaluation Criteria in Solid 
Tumours (RECIST) 1.0.
Statistical analysis
For statistical analysis, OS and PFS were defined, respec-
tively, as the interval between the first day of first-line 
chemotherapy until the time of the first occurrence of 
progression, death from any cause or to the date of last 
follow-up visit and as the interval between the first day 
of first-line chemotherapy to the date of death or to the 
date of the last follow-up visit. Analyses of PFS and OS 
curves were performed using the Kaplan–Meier method. 
We compared the response rates between the two groups 
using the Chi-square test.
Results
Characteristics of the patients
A total of 425 advanced gastric cancer patients treated 
with chemotherapy were included in our analysis. Males 
and females were 63 and 37 % respectively with a median 
age of 64  years (range 29–84  years). The two groups of 
patients resulted comparable for most of baseline char-
acteristics of clinical relevance (age, sex, ECOG PS, 
site of metastases, tumour histology, previous surgical 
resection, peritoneal diffusion, as shown in Table 1. The 
majority of the patients (76 %) had previously undergone 
surgery for their disease. Peritoneal tumour diffusion was 
present in 215 cases (50.6 %). Tumour involved gastroe-
sophageal junction in 18  % of cases. After disease pro-
gression, about 45  % of patients received a second-line 
chemotherapy.
Treatment
Two-hundred and sixteen patients (50.8 %) received three 
chemotherapeutic agents as first-line treatment (group 
A); chemotherapy included a platinum derivate and a 
fluoropyrimidine with the addition of an anthracycline 
(about 70 %), or mytomicin C (23 %) or docetaxel (5.5 %); 
a minority of patients (2  %) received a platinum-free 
combination (FAM regimen) as shown in Table 2. Two-
hundred and nine patients (49.2 %) received a two drugs 
regimen as first-line combination chemotherapy (group 
B); 199 patients received a fluorouracil based chemother-
apy with the addition of a second drug such as a platinum 
derivate (62 %), mytomicin C (27 %), irinotecan (6.7 %). 
Ten patients received a chemotherapy regimen which not 
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contained fluorouracil. A total of 191 (44.9  %) patients 
received second line chemotherapy. The percentage of 
patients receiving second line chemotherapy was found 
to be slightly higher in group B compared to group A 
(47.4 vs 42.6 %, p = 0.37). FOLFIRI (5-fluorouracil, leuco-
vorin and irinotecan) was the most commonly used regi-
men in this setting and 43.5 % of all patients who received 
second line chemotherapy received this combination. 
Other second line treatments included taxanes (pacli-
taxel or docetaxel), FOLFOX (5-fluorouracil, leucovorin 
and oxaliplatin) and combinations of 5-fluorouracil and 
mytomicin C.
Efficacy
In 387 patients with measurable disease, we observed 4 
(2 %) complete responses and 82 (42 %) partial responses 
in group A and 3 complete responses (1.5  %) and 54 
(28.1  %) partial responses in group B. 52 (26.7  %) and 
56 (29.3  %) patients achieved a stable disease as best 
response to first-line treatment in group A and B, respec-
tively (Table  3). The overall response rate observed in 
patients treated with a three-drugs first-line chemother-
apy (group A) was 44  %, significantly higher compared 
to response rate in group B (29.6  %), p  =  0.0005. The 
outcome of patients treated with a first-line three drugs 
regimen was better also in terms of PFS, with a median 
PFS of 7.3 months in group A compared to 4.5 months in 
group B, p = 0.0007 (Fig. 1). Overall Survival did not dif-
fer significantly between the two groups, with a median 
OS of 13  months for group A and of 11.8  months for 
group B, p = 0.84 (Fig. 2).
Toxicity
Most common adverse events to first-line chemotherapy 
are listed in Table  4. Grade 3–4 neutropenia was more 
common in patients treated with three drugs regimens 
(group A) compared to group B (43 vs 28  %) and also 
incidence of febrile neutropenia was higher in group A. 
Severe fatigue was found to be more common in group 
A (28 %) compared to group B (15 %) of patients. Other 
common treatment’s related toxicities were nausea and 
vomiting, diarrhea and peripheral neuropathy.
Discussion
Standard chemotherapy for advanced gastric cancer 
patients represents a matter of debate among the oncol-
ogy community. Although a recent meta-analysis dem-
onstrated a survival advantage for the use of three-drugs 
first-line regimens, a two drugs, cisplatin-based chemo-
therapy is still considered a preferred choice in many 
countries for both the daily practice and as reference arm 
in randomized trials.
In fact, the apparent small survival advantage and the 
toxicity profile linked to triplets chemotherapy regimens 
made the option of doublets regimens more attractive in 
this setting.
Table 1 Patients’ characteristics
Group A (3 drugs) Group B (2 drugs) p
Age
 Median (range), 
years
61 (29–79) 68 (32–84)
Sex
 M 138 128 0.64
 F 78 81
ECOG PS
 0–1 165 155 0.67
 2 51 54
Histotype
 Intestinal 127 133 0.36
 Diffuse 89 76




 Stomach 182 166
Surgery
 Yes 180 143 0.0005
  No 36 66
Neoadjuvant/Adjuvant chemotherapy
  Yes 74 62
  No 142 147 0.36
Metastatic site
 1 129 134 0.18
 ≥2 87 75
Peritoneal carcinosis
 Yes 118 97 0.9
 No 98 112
Second line chemotherapy
 Yes 92 99 0.37
 No 124 110
Table 2 First-line chemotherapy regimens administered 
in the two groups of patients
PELF (cisplatin, epirubicin, 5-FU and leucovorin), ECF (epirubicin, cisplatin 
and 5-FU), TCF (docetaxel, cisplatin, 5-FU), MMC (mytomicin C), FAM (5-FU, 
adriamycin, cyclofosfamid) CDDP (cisplatin), FOLFIRI (5-FU, leucovorin, 
irinotecan, irinotecan), IROX (irinotecan, oxaliplatin)
Group A N. patients Group B N. patients
PELF 138 (64 %) CDDP + 5-FU 86 (41 %)
ECF 12 (5.5 %) FOLFOX 43 (21 %)
CDDP + 5-FU + MMC 50 (23 %) 5-FU + MMC 56 (27 %)
TCF 12 (5.5 %) FOLFIRI 14 (6.7 %)
FAM 4 (2 %) CDDP + docetaxel 9 (4 %)
IROX 1 (0.3 %)
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Our retrospective analysis suggested that a three-
drugs first-line chemotherapy may be superior in terms 
of response rate and PFS to a two-drugs regimen in the 
treatment of advanced gastric cancer patients. Neverthe-
less, no significant difference in OS was demonstrated 
between the two treatments.
These results are in contrast with the findings from a 
few randomized trials demonstrating a benefit for three-
drug regimens versus traditional doublets. A modest 
benefit from the addition of an anthracycline to a two-
drugs platinum-based treatment has been demonstrated 
by meta-analyses (Wagner et al. 2006). Nevertheless, no 
randomized trial has confirmed this benefit and most of 
the trials have actually compared different three drugs 
regimen, as FAMTX, containing fluorouracil, doxoru-
bicin and methotrexate, vs ECF (epirubicin, cisplatin and 
infusional fluorouracil) (Webb et al. 1997) or ECF vs the 
combination of mytomicin, cisplatin and fluorouracil 
(MCF) (Ross et al. 2002).
The addition of taxanes to a platinum and 5-FU com-
bination has also been shown to improve the efficacy of 
treatment in gastric cancer. The V325 trial randomized 
445 advanced gastric cancer patients to docetaxel, cis-
platin and 5-FU (TCF) or cisplatin and 5-FU (CF) (Van 
Cutsem et  al. 2006). The trial showed that adding doc-
etaxel to CF significantly improved response rate (37 
vs 25  %, p  =  0.01) and prolonged Time To Progres-
sion (5.6  months; 95  % CI 4.9–5.9; vs 3.7  months; 95  % 
CI 3.4–4.5) and Overall Survival (9.2  months; 95  % CI 
8.4–10.6; vs 8.6 months; 95 % CI 7.2–9.5). These results 
demonstrated a small but significant advantage in over-
all survival for a first-line three-drugs regimen com-
pared to a doublet but they also showed an expected 
increase in treatment’s toxicity. For example, in the V325 
trial, the treatment with DCF resulted in an higher fre-
quency of grade 3 or 4 toxic effects, such as neutropenia 
(82 vs 57 %), febrile neutropenia (29 vs 12 %), diarrhoea 
(19 vs 9  %), and lethargy (19 vs 14  %) compared to the 
CF group. Our study confirmed these results, showing 
an higher incidence of toxicities, such as neutropenia 
and fatigue, in the group of patients treated with three 
drugs regimens. Nevertheless, other studies have evalu-
ated different schedules of taxanes-based three-drugs 
regimens, showing that tolerability of these treatments 
may be improved with the use of weekly schedule () Teb-
butt NC1, Cummins MM, Sourjina T et al. Randomised, 
non-comparative phase II study of weekly docetaxel 
with cisplatin and 5-fluorouracil or with capecitabine in 
oesophagogastric cancer: the AGITG ATTAX trial. Br J 
Cancer 2010).
We hypothesized that the lack of a significant differ-
ence in overall survival between patients treated with 
three or two drugs in first line, observed in our analysis, 
may be related to the influence of second line treatment 
in the outcome of patients. Increasing evidences support 
the use of a salvage treatment after progression to first-
line chemotherapy, but in the oldest phase III trials the 
use of a subsequent second-line treatment was restricted 
only to a small percentage of patients. A pooled analy-
sis including 1080 patients, from three phase III trials 
of first-line chemotherapy for advanced gastric cancer, 
Table 3 Response rate in patients with measurable disease treated with three vs two drugs first-line chemotherapy
CR complete response, PR partial response, SD stable disease, PD progressive disease, ORR overall response rate
Response rate Group A (3 drugs; n.pts 195) Group B (2 drugs; n.pts 192)
CR 4 (2 %) 3 (1.5 %)
PR 82 (42 %) 54 (28.1 %)
ORR (CR + PR) 86 (44 %) 57 (29.6 %) p = 0.005
SD 52 (26.7 %) 56 (29.3 %)
PD 57 (29.3 %) 79 (41.1 %)
Fig. 1 Kaplan-Meier curves for median progression-free survival (PFS) 
of advanced gastric cancer patients in group A (three-drugs first-line 
chemotherapy) (dotted line) and group B (two-drugs first-line chemo-
therapy) (thin line) (7.3 vs. 4.5 months, p = 0.0007)
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showed that 20  % of patients went on to receive a sec-
ond line chemotherapy with a 13  % response rate and 
a progression-free survival of 5.6  months (Chau et  al. 
2004). Also in the more recent REAL-2 study only 14 % 
of the patients received a second line treatment after 
progression.
Recently, a small phase III randomized trial evalu-
ated single-agent irinotecan compared to best support-
ive care in pre-treated advanced gastric cancer patients 
(Thuss-Patience et  al. 2011). The trial was closed early 
due to poor accrual, after the enrolment of 40 patients. 
The study demonstrated a statistically significant overall 
survival benefit for irinotecan over best supportive care 
alone, with a median OS of 4.0  months for the irinote-
can arm versus 2.4  months for the best supportive care 
arm (p  =  0.012, HR  =  0.48, 95  % CI 0.25–0.92). Simi-
lar results were achieved by another randomized phase 
III trial comparing second line treatment with either 
docetaxel or irinotecan to best supportive care in pre-
treated advanced gastric cancer patients (Parket al. 2011). 
Among the 202 randomized patients, a significant ben-
efit in OS (5.1 vs 3.8  months; p =  0.004) was observed 
for second-line chemotherapy over best supportive care. 
Another recent trial evaluated docetaxel in second line 
treatment of advanced gastric cancer and demonstrated a 
benefit in overall survival for chemotherapy compared to 
active symptoms control (Ford et al. 2014).
In our study the use of salvage treatment was well bal-
anced between the two groups of patients. FOLFIRI 
was the most used regimen in the second line setting. 
Therefore, our results seem to suggest that the sequen-
tial use of active agents, in advanced gastric cancer, may 
be equivalent to a more aggressive, simultaneous use of 
the drugs in terms of overall survival. The comparison 
of these different approaches has been already evalu-
ated in different gastrointestinal cancers. In particular, 
in advanced colorectal cancer, two randomized trials, 
CAIRO and FOCUS showed that staged strategies of 
a single agent fluoropyrimidine followed by a doublet 
combination are not inferior to up-front doublets in 
terms of overall survival (Koopman et al. 2007; Seymour 
et al. 2007). More recently, the use of a sequential strat-
egy has been assessed also in the treatment of advanced 
gastric cancer in a phase II trial with encouraging results 
(Loupakis et al. 2010). In this study, the authors evaluated 
a sequential strategy involving three different chemo-
therapy doublets containing cisplatin, irinotecan and 
docetaxel in combination with infused fluorouracil and 
folinic acid. The results obtained in terms of PFS and OS 
(6.8 and 11.1  months respectively) were comparable to 
those observed in trials using three-drugs first-line regi-
mens with a favourable safety profile.
However, given our observations suggesting an 
improved response rate and progression-free survival 
with triplets, we could speculate that this therapeu-
tic option may represent a first choice in patients with 
tumour related symptoms or bulky disease, where the 
chances to use a second-line treatment are less probable 
and a prompt disease control is needed.
Fig. 2 Kaplan-Meier curves for median overall survival (OS) of 
advanced gastric cancer patients in group A (three-drugs first-line 
chemotherapy) (dotted line) and group B (two-drugs first-line chemo-
therapy) (thick line) (13 vs. 11.8 months, p = 0.84)
Table 4 Most common adverse events to first-line chemo-
therapy in the two groups of patients
NCI-CTC toxicity criteria 1.0













Anemia 75 15 72 9
Neutropenia 78 43* 65 28
Trombocyto-
penia






67 16 61 14
Diarrhea 42 10 36 8
Stomatitis 35 7 29 6
Fatigue 71 28* 66 15
Peripheral 
neuropathy
36 14 28 8
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Considering the less favourable toxicity profile of a 
three-drugs first-line treatment, this option should be 
chosen after a careful assessment of patient’s perfor-
mance status and comorbidities, keeping in mind that 
maintaining the patient’s quality of life is a primary goal 
of treatment in metastatic setting. Indeed, in our analysis 
an high rate of febrile neutropenia was seen in patients 
treated with three-drug combination therapy. The ret-
rospective nature of the study is one of the limitations 
of this analysis with possible selection bias, together 
with the heterogeneity of chemotherapy regimens used, 
including some outdated or unusual regimens. Moreo-
ver, after the recent demonstration of efficacy of the 
anti-HER2 agent trastuzumab in the treatment of HER-2 
positive advanced gastric cancer (Bang et  al. 2010), the 
combination of trastuzumab with a chemotherapy dou-
blet (cisplatin with a fluoropyrimidine) represents the 
treatment of choice in this subset of patients.
Further prospective clinical trials, evaluating different 
chemotherapy sequences in the treatment of advanced 
gastric cancer, are warranted to improve patients’ out-
come and minimize the toxicity of treatment.
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